$KTTA

KTTA SEC Filings - Pasithea Therapeutics Corp 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for investors and traders to access Pasithea Therapeutics (KTTA) SEC filings, including annual, quarterly, and material event reports, alongside insider trading forms. Each filing is accompanied by an AI-generated summary, sentiment and impact scores, and end-of-day stock performance data. The platform aims to simplify access to critical regulatory disclosures with analytical insights and historical market reactions.

Original reporting
Published Apr 1, 2026, 11:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 1, 2026, 11:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$KTTA
Bullish
medium confidence
Mentioned
$KTTA · $KTTA
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$KTTABullishLow
01

Why it matters

The filings reinforce the company's ongoing development efforts and financial health, which are generally viewed positively by investors.

02

Market read

The filings are relevant for investors monitoring biotech regulatory disclosures but have limited immediate trading impact.

03

What to watch

Potential upcoming clinical trial results or regulatory decisions could alter the outlook significantly.

Timing: Long-term

Background

Pasithea Therapeutics is a biotech company focused on neurological and psychiatric disorders. Its SEC filings include annual reports, quarterly updates, and material event disclosures.

Company-level read

Ticker impact

$KTTABullishMedium confidence
Context

SEC filings provide regulatory and financial disclosures that can influence investor sentiment and stock performance.

Expected impact

Moderate upward movement in the short to medium term.

Evidence & confidence

The filings suggest continued progress and stability, which may support stock appreciation. However, the overall market sentiment is only somewhat bullish, and external factors could influence the stock's trajectory.

$KTTANeutralLow confidence
Context

Low relevance due to the specific focus on regulatory filings rather than market-moving news or earnings surprises.

Expected impact

Minimal short-term price change.

Evidence & confidence

Regulatory filings are routine and do not typically cause significant price swings unless they contain unexpected material information.

Market effects

Potential positive influence on life sciences sector due to ongoing clinical developments.

Limited, as filings are company-specific and do not indicate regional market shifts.

Minimal, as the filings pertain to a single biotech company.

Counterpoint

Some investors may interpret the lack of significant positive surprises as cautionary, suggesting a wait-and-see approach.

Key entities

  • Pasithea Therapeutics Corp

    Biotech firm specializing in neurological treatments.

  • SEC

    Securities and Exchange Commission, overseeing disclosures.

Related articles

$KTTAMedAI 9/10

Pasithea's PAS-004 Receives FDA Orphan Drug Designation In Treating AL. Sclerosis

Pasithea Therapeutics (KTTA) said the U.S. FDA granted Orphan Drug Designation to PAS-004 for amyotrophic lateral sclerosis (ALS). The company said PAS-004 is a macrocyclic MEK inhibitor and is in Phase 1 trials in advanced cancer and Phase 1/1b trials in NF1-associated plexiform neurofibromas. Orphan status can bring tax credits, fee exemptions, and up to seven years’ exclusivity after approval.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.